ANIK Anika Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 898437 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY52.5%
TTM net income YoY94.7%
TTM EPS YoY94.3%
Revenue 3-yr CAGR-8.9%
Net income 3-yr CAGR—
Margins
Gross margin63.4%
Operating margin-2.1%
Net margin-1.4%
FCF margin1.9%
EBITDA margin2.5%
Returns
ROE-1.2%
ROA-0.9%
ROIC (approx.)-2.3%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets27.4%
Debt / equity0.00x
Current ratio3.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-4.24x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $30.59M | $32.61M | $29.61M | $30.61M | $27.82M | $28.22M | $26.17M | -$1.29M |
| Cost of revenue | $11.76M | $11.37M | $10.62M | $11.44M | $12.23M | $13.86M | $11.49M | -$23.86M |
| Gross profit | $18.84M | $21.24M | $19.00M | $19.18M | $15.58M | $14.36M | $14.68M | $22.57M |
| R&D expense | $7.89M | $7.34M | $6.71M | $6.45M | $6.95M | $6.31M | $6.06M | $2.74M |
| SG&A expense | $11.65M | $10.95M | $17.77M | $12.08M | $11.87M | $12.23M | $12.91M | -$4.89M |
| Operating income | -$712,000 | $2.95M | -$5.49M | $646,000 | -$3.23M | -$4.18M | -$4.28M | $27.82M |
| Pretax income | -$322,000 | $3.38M | -$4.82M | $764,000 | -$2.24M | -$3.97M | -$3.87M | $39,000 |
| Income tax | -$11,000 | $71,000 | $235,000 | -$1.04M | $939,000 | $681,000 | $89,000 | $2.87M |
| Net income | -$311,000 | $3.31M | -$5.06M | $292,000 | -$2.33M | -$3.97M | -$4.87M | -$21.86M |
| EBITDA | $727,000 | $4.45M | -$4.08M | $1.96M | -$1.83M | -$2.88M | -$2.90M | $29.38M |
| EPS (basic) | -0.02 | 0.25 | -0.37 | — | -0.16 | -0.28 | -0.34 | — |
| EPS (diluted) | -0.02 | 0.24 | -0.37 | — | -0.16 | -0.28 | -0.34 | — |
| Weighted avg. shares (diluted) | 13.39M | 13.72M | 13.53M | — | 14.42M | 14.52M | 14.30M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $44.96M | $38.41M | $41.02M | $57.48M | $57.99M | $53.17M | $53.37M | $55.63M |
| Short-term investments | — | — | $25.77M | $23.69M | $22.19M | $23.95M | $21.99M | $23.59M |
| Receivables | $24.25M | $29.06M | $25.77M | $23.69M | $22.19M | $23.95M | $21.99M | $23.59M |
| Inventory | $30.35M | $28.57M | $22.84M | $18.79M | $16.28M | $16.92M | $21.34M | $23.81M |
| Current assets | $103.05M | $99.19M | $93.56M | $103.36M | $101.59M | $99.32M | $102.51M | $113.65M |
| PP&E, net | $40.74M | $40.10M | $39.72M | $40.32M | $40.68M | $40.68M | $40.46M | $38.99M |
| Goodwill | $7.78M | $7.83M | $7.89M | $8.05M | $8.05M | $8.06M | $7.42M | $7.12M |
| Intangibles | $1.65M | $1.65M | $1.65M | $1.65M | $1.65M | $1.66M | $2.28M | $2.49M |
| Total assets | $189.60M | $183.47M | $179.39M | $190.27M | $189.44M | $187.68M | $190.60M | $202.74M |
| Current liabilities | $26.73M | $22.15M | $20.97M | $21.91M | $19.09M | $16.08M | $17.90M | $23.31M |
| Total liabilities | $52.02M | $46.19M | $45.49M | $46.80M | $42.63M | $40.01M | $42.21M | $48.75M |
| Shareholders' equity | $137.58M | $137.28M | $133.90M | $143.47M | $146.81M | $147.67M | $148.40M | $153.99M |
| Shares outstanding | 13.39M | 13.38M | 13.36M | 13.89M | 14.42M | 14.42M | 14.34M | 14.42M |
| Cash flow statement | ||||||||
| Operating cash flow | $8.38M | -$684,000 | -$4.85M | $4.64M | $6.87M | -$189,000 | -$130,000 | $1.58M |
| Capital expenditure | $1.66M | $1.45M | $1.43M | $648,000 | $1.89M | $1.47M | $2.82M | $1.31M |
| Free cash flow | $6.72M | -$2.13M | -$6.28M | $3.99M | $4.98M | -$1.66M | -$2.95M | $275,000 |
| Investing cash flow | -$1.76M | -$1.28M | -$1.24M | $198,000 | -$1.73M | -$539,000 | $1.67M | -$1.31M |
| Financing cash flow | -$27,000 | -$701,000 | -$10.35M | -$5.28M | -$13,000 | $179,000 | -$5.44M | -$5.35M |
| Depreciation & amortization | $1.44M | $1.50M | $1.41M | $1.32M | $1.40M | $1.30M | $1.38M | $1.56M |
| Stock-based compensation | $4.24M | $1.83M | $6.64M | $2.46M | $2.21M | $2.55M | $2.86M | $2.25M |
| Share buybacks | $0 | $853,000 | $8.69M | $5.51M | $0 | $0 | $3.97M | $5.58M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.